Joshua Cohen

Social justice advocate. Coffee drinker. Obsessive @spotify playlist maker. Husband. Father.

Categories
N/A
Content Types
N/A
More Information
Location|Languages
Publications

Published Content

26
Edge In U.S. Cancer Drug Development Spurred By Regulatory And Reimbursement Policies
forbes.comArticle
Edge In U.S. Cancer Drug Development Spurred By Regulatory And Reimbursement Policies
October, 22 2018
Improving Drug Price Transparency: From Removing Pharmacy Gag Clauses To Reforming The Rebate System
forbes.comArticle
Improving Drug Price Transparency: From Removing Pharmacy Gag Clauses To Reforming The Rebate System
October, 17 2018
Measuring Well-Being: It's More Than GDP
forbes.comArticle
Measuring Well-Being: It's More Than GDP
October, 15 2018
Why It's Not So Simple To Standardize The Guides Insurers Use To Pay For Off-Label Cancer Drugs
forbes.comArticle
Why It's Not So Simple To Standardize The Guides Insurers Use To Pay For Off-Label Cancer Drugs
October, 10 2018
Possible Removal Of Pre-Existing Conditions Protections
forbes.comArticle
Possible Removal Of Pre-Existing Conditions Protections
October, 8 2018
Cigna And Express Scripts Deal: Virtues Of Vertical Integration
forbes.comArticle
Cigna And Express Scripts Deal: Virtues Of Vertical Integration
October, 3 2018
Why Payers Sometimes Restrict Access To Single Tablet Regimens For HIV Patients
forbes.comArticle
Why Payers Sometimes Restrict Access To Single Tablet Regimens For HIV Patients
October, 1 2018
To Include Or Not Include Drug Prices In DTC Ads
forbes.comArticle
To Include Or Not Include Drug Prices In DTC Ads
September, 24 2018
Will CVS Caremark Make ICER The American NICE?
forbes.comArticle
Will CVS Caremark Make ICER The American NICE?
September, 20 2018
Medicare Advantage Plan Proposed Use Of Step Therapy For Part B Drugs
forbes.comArticle
Medicare Advantage Plan Proposed Use Of Step Therapy For Part B Drugs
September, 17 2018
The Curious Case Of Gleevec Pricing
forbes.comArticle
The Curious Case Of Gleevec Pricing
September, 12 2018
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
forbes.comArticle
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
September, 10 2018
Tanezumab's Phase 3 Results: A Promising Sign For Non-Opioid Pain Treatments
forbes.comArticle
Tanezumab's Phase 3 Results: A Promising Sign For Non-Opioid Pain Treatments
September, 6 2018
Medicaid To Introduce Value-Based Drug Pricing
forbes.comArticle
Medicaid To Introduce Value-Based Drug Pricing
September, 4 2018
Where Medication Therapy Management/Telehealth Services Deliver Value
forbes.comArticle
Where Medication Therapy Management/Telehealth Services Deliver Value
August, 24 2018
We're All Suffering From Something -- Is This A Problem?
forbes.comArticle
We're All Suffering From Something -- Is This A Problem?
August, 21 2018
Increasing Numbers of Americans Want Single Payer, But Is That What They Want?
forbes.comArticle
Increasing Numbers of Americans Want Single Payer, But Is That What They Want?
August, 16 2018
Has Amyloid-Based Research Turned The Corner?
forbes.comArticle
Has Amyloid-Based Research Turned The Corner?
August, 13 2018
Better U.S. Patient Access To Cancer Drugs Comes At A Price
forbes.comArticle
Better U.S. Patient Access To Cancer Drugs Comes At A Price
August, 9 2018
Changes To Drug Prices: Gestures And Real Policy Shifts
forbes.comArticle
Changes To Drug Prices: Gestures And Real Policy Shifts
August, 7 2018
Taking A Wider View Of Precision Oncology
forbes.comArticle
Taking A Wider View Of Precision Oncology
August, 2 2018
Right To Try For Some Raises False Hopes For Many
forbes.comArticle
Right To Try For Some Raises False Hopes For Many
July, 27 2018
Precision Medicine Success Hinges On Diagnostics' Clinical Utility
forbes.comArticle
Precision Medicine Success Hinges On Diagnostics' Clinical Utility
July, 23 2018
'Diseases Of Despair' Contribute To Declining U.S. Life Expectancy
forbes.comArticle
'Diseases Of Despair' Contribute To Declining U.S. Life Expectancy
July, 19 2018
Bold Rx-To-OTC Switches On The Horizon? Naloxone, Perhaps
forbes.comArticle
Bold Rx-To-OTC Switches On The Horizon? Naloxone, Perhaps
July, 16 2018
Gradual Progress In Precision Non-Oncology, But Challenges Persist
forbes.comArticle
Gradual Progress In Precision Non-Oncology, But Challenges Persist
July, 10 2018
Authorship Stats
1Sites26Projects17,804Words
About
Joshua Cohen is a writer who has produced content for forbes.com
Key Phrases
Cancer Drugs, Drug Prices, Single Payer, Health Outcomes, Healthcare System, Step Therapy, Cancer Drug, Companion Diagnostics, Off Label Uses, Precision Medicine
© ClearVoice, Inc.